Website & contact details
- Website
Loqus23 Therapeutics Limited
- Incorporated
- 29 March 2019 (7 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Cyrus MozayeniRogier Wouter Rooswinkel
- Accounts type
- Small
- Region
- East of England
- Address
- Suite 7 Mcclintock BuildingGranta ParkGreat AbingtonCB21 6GP
Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 31 March 2025
- Conf. stmt due
- 11 April 2027
- Last conf. stmt
- 28 March 2026
Charges
- Total
- 3
- Outstanding
- 1
- Part satisfied
- 0
- Satisfied
- 2
Officers 5 active
Officer details are public data from the Companies House register.
Mozayeni, Cyrus, Dr
Director · Appointed 30 January 2025
American
Born July 1974 (52)
Rooswinkel, Rogier Wouter, Dr
Director · Appointed 6 September 2024
Dutch
Born August 1983 (43)
Director · Appointed 9 November 2021
Swiss
Born December 1972 (53)
Director · Appointed 3 March 2020
Luxembourger
Born September 1982 (44)
Director · Appointed 29 March 2019
British
Born February 1973 (53)
Officer history (4 former)
22 January 2026
Resigned Ivarsson, Melanie Jane, Dr as Director
30 January 2025
Appointed Mozayeni, Cyrus, Dr as Director
6 September 2024
Appointed Rooswinkel, Rogier Wouter, Dr as Director
12 December 2021
Appointed Ivarsson, Melanie Jane, Dr as Director
9 November 2021
9 November 2021
Resigned Sandham, Andrew Peter as Director
3 March 2020
3 March 2020
2 March 2020
5 September 2019
Appointed Sandham, Andrew Peter as Director
29 March 2019
29 March 2019
29 March 2019
Ownership 2 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 29 March 2019
Owns 25–50% of shares
Holds 25–50% of voting rights
Limited Partnership
Reg. no. Sl021984
Corporate entity · Notified 29 March 2019
Owns 25–50% of shares
Holds 25–50% of voting rights
Corporate
Reg. no. Oc416321
Former controllers (2)
6 September 2024
Ceased Novartis AG — Owns 50–75% of shares
29 March 2019
Ceased SV Health Managers LLP — Has significant influence or control
Group structure 21 shown
Ownership group derived from the Companies House PSC register
DDF 2 FP GP LLP Holds 25–50% of voting rights
DDF 2 FP LP Has significant influence or control
DDF 2 GP LLP Holds 25–50% of voting rights
SV Bco I FP GP LLP Holds 25–50% of voting rights
SV Bco I FP LP Right to appoint and remove a person
SV Bco I GP LLP Holds 25–50% of voting rights
Serenza Therapeutics Ltd Owns 25–50% of shares
SV Health Managers LLP Holds 75–100% of voting rights
Dementia Discovery GP LP Has significant influence or control
Harness Therapeutics Limited Holds 75–100% of voting rights
Loqus23 Therapeutics Limited This company Owns 25–50% of shares
SV DDF Number 1 Limited Owns 75–100% of shares
Dementia Discovery General Partner LLP Holds 75–100% of voting rights
SV DDF Number 2 Limited Owns 75–100% of shares
SV7 (Imf) FP LP Has significant influence or control
SV7 (Imf) FP GP LLP Holds 25–50% of voting rights
SV7 (Imf) GP LLP Holds 25–50% of voting rights
Cellinta Ltd Owns 75–100% of shares
SV8 Bio FP GP LLP Holds 25–50% of voting rights
SV8 Biotech FP LP Part right to 75–100% of surplus assets
Filings
Filing history not loaded yet. See it on Companies House
Other companies in this industry
Newcastle Upon Tyne
Edinburgh
Edinburgh
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →